Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the approval of its licensed product, Botulinum Toxin Type A for Injection, by China’s National Medical Products Administration. The product, aimed at reducing the appearance of severe glabellar lines in adults, marks a significant step for the subsidiary Fosun Pharmaceutical Industrial. The board assures the accuracy and legality of the announcement’s content.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
